Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
2 weeks screening period, 4 weeks run-in period, 24 weeks double-blind treatment period, to
evaluate the Safety and Efficacy of Retagliptin Plus Henagliflozein added to Metformin
compared to Retagliptin or Henagliflozein in combination with Metformin in Subjects with Type
2 Diabetes who have Inadequate Glycemic Control on Metformin Alone